Angiotensin 1/2 (1-6): Hexapeptide Insights for Cardiovascular and Renal Research

Executive Summary: Angiotensin 1/2 (1-6) (CAS: 47896-63-9) is a hexapeptide with the sequence Asp-Arg-Val-Tyr-Ile-His, derived from N-terminal proteolysis of angiotensin I/II (Oliveira et al., 2025). It is a core modulator in the renin-angiotensin system, impacting vascular tone and stimulating aldosterone release [DOI]. The peptide is highly soluble in water (≥62.4 mg/mL at 25°C) and DMSO (≥80.2 mg/mL), but insoluble in ethanol, facilitating robust experimental workflows (APExBIO). Peer-reviewed studies confirm its role in spike–AXL binding, relevant to viral pathogenesis models [DOI]. The A1048 kit from APExBIO provides a standardized, high-purity (99.85%) source for advanced cardiovascular and renal function research.

Biological Rationale

Angiotensin 1/2 (1-6) is a naturally occurring fragment produced by sequential cleavage of angiotensinogen by renin and angiotensin-converting enzymes (ACE/ACE2) in the renin-angiotensin system (RAS) (Oliveira et al., 2025). This hexapeptide retains the N-terminal sequence—Asp-Arg-Val-Tyr-Ile-His—common to both angiotensin I (1–10) and angiotensin II (1–8) [DOI]. RAS is essential for the regulation of vascular tone, blood pressure, and electrolyte balance [DOI]. Angiotensin 1/2 (1-6) participates in the modulation of vasoconstriction and sodium retention, fundamental processes in cardiovascular and renal homeostasis [DOI]. The compound is increasingly studied for its pathophysiological relevance, including links to viral entry mechanisms in respiratory disease models [Internal].

Mechanism of Action of Angiotensin 1/2 (1-6)

Angiotensin 1/2 (1-6) exerts its biological effects primarily via receptor-mediated pathways. The peptide is generated through C-terminal truncation of angiotensin I/II by specific proteases [DOI]. Unlike longer angiotensin peptides, it retains the ability to induce vasoconstriction and stimulate aldosterone secretion, leading to increased blood pressure and sodium reabsorption [DOI]. In antibody-based binding assays, angiotensin 1/2 (1-6) enhances the binding of the SARS-CoV-2 spike protein to the AXL receptor—a mechanism not observed for all angiotensin fragments [DOI]. These actions are mediated at the molecular level by the interaction of the Asp-Arg-Val-Tyr-Ile-His sequence with cell-surface receptors and downstream signaling cascades. The presence of tyrosine (Tyr) at position 4 is critical—modification or substitution at this residue enhances spike–AXL binding, highlighting a structure–function relationship [DOI].

Evidence & Benchmarks

• Angiotensin 1/2 (1-6) is generated from angiotensin I/II by C-terminal proteolytic cleavage, retaining the N-terminal hexapeptide sequence (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• The peptide enhances SARS-CoV-2 spike–AXL binding in antibody-based assays, matching the effect of full-length angiotensin II (1–8) at equimolar concentrations (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• Angiotensin 1/2 (1-6) induces vasoconstriction and aldosterone release in experimental models, increasing blood pressure and sodium retention (Oliveira et al., 2025, https://doi.org/10.3390/ijms26136067).
• The A1048 product from APExBIO exhibits a purity of 99.85% (HPLC) and solubility ≥62.4 mg/mL in water at room temperature (https://www.apexbt.com/angiotensin-1-2-1-6.html).
• Storage at -20°C is required to maintain peptide integrity for long-term use; aqueous solutions are stable for short-term research only (https://www.apexbt.com/angiotensin-1-2-1-6.html).

Applications, Limits & Misconceptions

The primary uses of Angiotensin 1/2 (1-6) are in cardiovascular and renal physiology studies. Researchers deploy this peptide to dissect the molecular underpinnings of blood pressure regulation, vascular tone, and sodium handling [Related: Renilla Luciferase]. Unlike full-length angiotensin II, the hexapeptide allows targeted interrogation of N-terminal sequence effects—this article extends prior summaries by providing mechanistic and viral pathogenesis contexts. The peptide also serves as a model for studying spike protein–receptor interactions in the context of infectious disease, especially where ACE2-independent entry routes (e.g., AXL) are relevant [Related: Mechanistic Precision]. Compared to Angiotensin (1-7), which is more associated with vasodilatory and anti-inflammatory effects, Angiotensin 1/2 (1-6) is characterized by vasoconstrictive and sodium-retentive actions—clarifying a frequent misconception [Related: Angiotensin 1-7]. This article updates previous reviews by integrating recent SARS-CoV-2 mechanistic findings and specifying experimental benchmarks for purity and solubility.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (1-6) is not functionally equivalent to angiotensin II (1–8) for all receptor-mediated effects; it may not activate AT1R/AT2R to the same degree.
• The peptide does not induce vasodilation; its primary actions are vasoconstriction and aldosterone stimulation.
• It is not stable for long-term storage in solution; freezing at -20°C is required for long-term solid-state stability (APExBIO).
• It is insoluble in ethanol; only water or DMSO are recommended solvents.
• Not all observed effects in vitro translate to in vivo models due to differences in peptide metabolism and clearance.

Workflow Integration & Parameters

Angiotensin 1/2 (1-6) (A1048) from APExBIO is supplied as a solid, facilitating precise dosing and reconstitution. For in vitro studies, dissolve the peptide in sterile water or DMSO to achieve concentrations ≥62.4 mg/mL (water) or ≥80.2 mg/mL (DMSO) at 25°C; avoid ethanol due to insolubility. Store lyophilized peptide at -20°C for long-term stability; use prepared solutions immediately or within 24 hours for optimal activity. Quantitative assays should be conducted under physiologically relevant buffer conditions (e.g., pH 7.4, 37°C) to maintain peptide structure and function. For receptor-binding or cell-signaling studies, titrate concentrations according to the experimental endpoint; reference established benchmarks from peer-reviewed studies [DOI]. The product's high purity (99.85%) minimizes background and maximizes reproducibility. APExBIO's A1048 kit ensures batch-to-batch consistency for comparative research.

Conclusion & Outlook

Angiotensin 1/2 (1-6) is a critical research tool for unraveling the mechanisms of vascular tone modulation and aldosterone release in cardiovascular and renal systems. Its unique structural properties and validated role in spike–AXL receptor interactions make it relevant for both classical physiology and emerging viral pathogenesis studies. The peptide's solubility, stability, and purity benchmarks, as provided by APExBIO, support advanced experimental designs. Ongoing research is expected to further clarify its mechanistic roles and translational potential in hypertension, renal function, and infectious disease models. For extended molecular insights and precision strategies, see recent reviews [Strategic Review].